About

Biomea Fusion

We are a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with metabolic disease, obesity and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.

We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.

Biomea Fusion, Inc. was formed in 2017 by a small group of biotech executives. We came together after a career in drug design and development with the common goal of achieving better therapies for patients.

Even with the extensive knowledge and technology that has produced today’s targeted therapies, there remains much room for improvement. Over the past years, we developed the Biomea FUSION™ System to take a substantial leap forward in drug development. Most drugs are reversibly binding to their target, requiring constant exposure, which can lead to a toxic side effect profile while often only marginally inhibiting the target.

We are focused on covalently bound drugs, which are commonly ignored due to their design and chemistry complexities.

We believe that covalently bound therapies can achieve a more constant inhibition of the targeted pathway with much less drug applied, and a reduced burden on the patient. We strive to create patient-friendly therapies that provide long, durable responses against aggressive tumors.